Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 284

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials

Monami, M., Nardini, C., Mannucci, E. · 2014 · Diabetes, Obesity and Metabolism

Abstract

Aims: Sodium glucose co‐transport‐2 (SGLT‐2) inhibitors, a new class of glucose‐lowering agents, reduce tubular glucose reabsorption, producing a reduction of blood glucose without stimulating insulin release. The aim of the present meta‐analysis is the assessment of the overall efficacy and safety profile of these drugs. Methods: A meta‐analysis was performed including all trials with a duration of at least 12 weeks, comparing a SGLT‐2 inhibitor with a non‐SGLT‐2 inhibitor agent in type 2 diabetes. The principal outcome of this analysis was the effect of SGLT‐2 inhibitors on HbA1c at 12, 24 and 52 weeks. Hypoglycaemia, genital and urinary infections were retrieved and combined to calculate Mantel–Haenszel odds ratio (MH‐OR). Furthermore, data on body mass index (BMI), endpoint fasting plasma glucose, systolic and diastolic blood pressure, creatinine, hematocrit and lipid profile were collected. Results: Among placebo‐controlled trials, HbA1c reduction at 12, 24 and 52 weeks was 0.5 [0.4; 0.6], 0.6 [0.6; 0.5] and 0.6 [0.7; 0.5]%. In placebo‐controlled studies, 24‐week reduction of HbA1c with SGLT‐2 inhibitors was greater in trials enrolling patients with a lower mean age and duration of diabetes, and a higher baseline BMI, HbA1c and fasting glucose. In placebo‐controlled trials, SGLT‐2 inhibitors determined a weight loss during the first 24 weeks, which was maintained up to 52 weeks. Conclusions: SGLT‐2 inhibitors are effective in the treatment of type 2 diabetes, providing additional benefits, such as weight loss, reduction of blood pressure and increase in high‐density lipoprotein (HDL)‐cholesterol. Apart from genital and urinary infections, rather frequent but usually mild, SGLT‐2 inhibitors appear to be well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12244

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

Metadata

Authors
Monami, M., Nardini, C., & Mannucci, E.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2013-12-29
Volume
16
Issue
5
Pages
457-466
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1664963969
Cited by
284
References
32
FWCI
17.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.